Thyroglobulin measurement by highly sensitive assays: Focus on laboratory challenges

Clinical Chemistry and Laboratory Medicine

Volumn 53, Issue 9, 2015, Pages 1301-1314

  Giovanella, Luca ^a   Feldt Rasmussen, Ulla ^b   Verburg, Frederik A ^c   Grebe, Stephan K ^d   Plebani, Mario ^e   Clark, Penelope M ^f  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d MAYO CLINIC   (United States)

^e UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^f QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

differentiated thyroid carcinoma; functional sensitivity; immunoassay; limit of quantification; thyroglobulin

Indexed keywords

THYROGLOBULIN; THYROGLOBULIN ANTIBODY;

ANTIBODY BLOOD LEVEL; ASPIRATION CYTOLOGY; ECHOGRAPHY; FINE NEEDLE ASPIRATION CYTOLOGY; HUMAN; IMMUNOASSAY; INCUBATION TIME; LABORATORY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LYMPH NODE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUALITY CONTROL; REVIEW; SENSITIVITY ANALYSIS; STANDARDIZATION; THYROGLOBULIN ASSAY; VALIDATION PROCESS; ARTIFACT; BLOOD; BLOOD ANALYSIS; PATHOLOGY; PROCEDURES; STANDARD; STANDARDS;

ARTIFACTS; BLOOD CHEMICAL ANALYSIS; HUMANS; LIMIT OF DETECTION; LYMPH NODES; REFERENCE STANDARDS; THYROGLOBULIN;

EID: 84938540205     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0813     Document Type: Review

References (73)

1. Grebe SK. Diagnosis and management of thyroid carcinoma: focus on serum thyroglobulin. Expert Rev Endocrinol Metab 2009;4:25-43.
2. Pacini F. Follow-up of differentiate thyroid cancer. Eur J Nucl Med 2002;29:492-6.
3. Giovanella L. Highly sensitive thyroglobulin measurements in differentiated thyroid carcinoma management. Clin Chem Lab Med 2008;46:1067-73.
4. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787-803.
5. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214.
6. Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid 2002;12:37-43.
7. Wartofsky L. Using baseline and recombinant human TSHstimulated Tg measurements to manage thyroid carcinoma without diagnostic (131)I scanning. J Clin Endocrinol Metab 2000;87:1486-9.
8. Wunderlich G, Zophel K, Crook L, Smith S, Smith BR, Franke WG. A high-sensitivity enzyme-linked immunosorbent assay for serum thyroglobulin. Thyroid 2001;11:819-24.
9. Iervasi A, Iervasi G, Bottoni A, Boni G, Annicchiarico C, Di Cecco P, et al. Diagnostic performance of a new highly sensitive thyroglobulin immunoassay. J Endocrinol 2004;182:287-94.
10. Giovanella L, Treglia G, Sadeghi R, Trimboli P, Ceriani L, Verburg FA. Unstimulated high-sensitive thyroglobulin in followup of differentiated thyroid cancer patients: a meta-analysis. J Clin Endocrinol Metab 2014;99:440-7.
11. Giovanella L, Clark P, Chiovato L, Duntas LH, Elisei R, Feldt-Rasmussen U, et al. Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper. Eur J Endocrinol 2014;171:R33-46.
12. Perros P, Boelaert K, Colley S, Evans C, Evans RM, Gerrard G, et al. British Thyroid Association Guidelines for the management of thyroid cancer, 3rd ed. Available from: www.britishthyroid-association.org/Guidelines/Docs/BTA-DTC-guidlines. pdf Accessed 7 June, 2014.
13. Sadler WA, Smith MH. Use and abuse of imprecision profile. Some pitfall illustrated by comparing and plotting confidence intervals. Clin Chem 1990;36:1346-50.
14. Sheehan C, He J, Smith M. Method evaluation-a practical guide. In: Wild D, editor. The immunoassay handbook, 4th ed. Oxford: Elsevier, 2013:395-402.
15. Ross HA, Netea-Maier RT, Schakenraad E, Bravenboer B, Hermus AR, Sweep FC. Assay bias may invalidate decision limits and affect comparability of serum thyroglobulin assay methods: an approach to reduce interpretation differences. Clin Chim Acta 2008;394:104-9.
16. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Gutler RB, Singer PA, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998;83:1121-7.
17. Verburg FA, Hartmann D, Grelle I, Giovanella L, Buck AK, Reiners C. Relationship between antithyroglobulin autoantibodies and thyroglobulin recovery rates using different thyroglobulin concentrations in the recovery buffer. Horm Metab Res 2013;45:728-35.
18. Castagna MG, Tala Jury HP, Cipri C, Belardini V, Fioravanti C, Pasqui L, et al. The use of ultrasensitive thyroglobulin assays reduces but does not abolish the need for TSH stimulation in patients with differentiated thyroid carcinoma. J Endocrin Invest 2011;34:e219-23.
19. Schlumberger M, Hitzel A, Toubert ME, Corone C, Troalen F, Schlageter MH, et al. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab 2007;92:2487-95.
20. Demers LM, Spencer CA, editors. National Academy of Clinical Biochemistry Guideline (Archived). Laboratory Support for the diagnosis and management of thyroid disease. Available from: http://www.aacc.org/members/nacb/Archive/LMPG/ThyroidDisease/ Pages/ThyroidDiseasePDF.aspx. Accessed 16 June, 2014.
21. Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev 2008;29(Suppl 1):S49-52.
22. CLSI. Protocols for determination of limits of detection and limits of quantification: approved guidelines, 2nd ed. EP17-A. CLSI: Wayne, PA, 2012.
23. Giovanella L, Bongiovanni M, Trimboli P. Diagnostic value of thyroglobulin assay in cervical lymph node fine-needle aspirations for metastatic differentiated thyroid cancer. Curr Opin Oncol 2013;25:6-13.
24. Rosario PW, Dos Santos JB, Calsolari MR. Follow-up of patients with low-risk papillary thyroid carcinoma and undetectable basal serum thyroglobulin after ablation measured with a sensitive assay: a prospective study. Horm Metab Res 2013;45:911-4.
25. Malandrino P, Latina A, Marescalco S, Spadaro A, Regalbuto C, Fulco RA, et al. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin. J Clin Endocrinol Metab 2011;96:1703-9.
26. Grani G, Fumarola A. Thyroglobulin in lymph node fine-needle aspiration washout: a systematic review and meta-analysis of diagnostic accuracy. J Clin Endocrinol Metab 2014;99:1970-62.
27. Boot CS, Mahon BS, Bramhall SR, Clark PM. Validation of carcinoembryonic antigen and carbodhydrate antigen 19-9 measurements in pancreatic cyst fluid with a serum-based immunoassay. Clin Chem 2010;56:1351-61.
28. Jeon MJ, Park JW, Han JM, Yim JH, Song DE, Gong G, et al. Serum antithyroglobulin antibodies interfere with thyroglobulin detection in fine-needle aspirates of metastatic neck nodes in papillary thyroid carcinoma. J Clin Endocrinol Metab 2013;98:155-60.
29. Rosario PW, Purisch S. Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4 < 1 ng/ml determined by traditional assays? Clin Endocrinol 2008;68:338-42.
30. Giovanella L, Ceriani L, Suriano S, Crippa S. Thyroglobulin measurement on fine-needle washout fluids: influence of sample collection methods. Diagn Cytopathol 2009;37:42-4.
31. Giovanella L, Ceriani L, Ghelfo A. Redefining functional sensitivity of thyroglobulin assay on Immulite platform: implications in thyroid cancer management. Clin Chem Lab Med 2007;45:1523-4.
32. Kato R, Maruyama M, Sekino T, Kasuga Y. A new assay for thyroglobulin concentration in serum using monoclonal antibodies against synthetic peptides. Clin Chim Acta 2000;298:69-84.
33. Hoofnagle AN, Becker JO, Wener MH, Heinecke JW. Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. Clin Chem 2008;54:1796-804.
34. Clarke NJ, Zhang Y, Reitz RE. A novel mass spectrometry-based assay for the accurate measurement of thyroglobulin from patient samples containing antithyroglobulin autoantibodies. J Investig Med 2012;60:1157-63.
35. Grebe SK. Soluble thyroid tumor markers-old and new challenges and potential solutions. NZ Instit Med Lab Sci J 2013;67:76-87.
36. Spencer CA, Lopresti JS. Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. Nature Clin Pract Endocrinol Metab 2008; 4:223-33.
37. Clark PM. Laboratory services for thyroglobulin and implications for monitoring of differentiated thyroid cancer. J Clin Pathol 2009;62:402-6.
38. Feldt-Rasmussen U, Schlumberger M. European inter-laboratory comparison of serum thyroglobulin measurement. J Endocrinol Invest 1988;11:175-81.
39. Feldt-Rasmussen U, Profilis C, Colinet E, Black E, Bornet H, Bourdoux P, et al. Human thyroglobulin reference material (CRM 457). 1st Part: assessment of homogeneity, stability and immunoreactivity. Ann Biol Clin (Paris) 1996;54:337-42.
40. Feldt-Rasmussen U, Profilis C, Colinet E, Black E, Bornet H, Bourdoux P, et al. Human thyroglobulin reference material (CRM 457). 2nd Part: physicochemical characterization and certification. Mol Cell Endocrinol 1966;116:165-72.
41. Clark P, Franklyn J. Can we interpret serum thyroglobulin results? Ann Clin Biochem 2012;49:313-22.
42. Feldt-Rasmussen U, Rasmussen AK. Autoimmunity in differentiated thyroid cancer: significance and related clinical problems. Hormones (Athens) 2010;9:109-17.
43. Crane MS, Strachan MW, Toft AD, Beckett GJ. Discordance in thyroglobulin measurements by radioimmunoassay and immunometric assay: a useful means of identifying thyroglobulin assay interference. Ann Clin Biochem 2013; 50:421-32.
44. Persoon AC, Links TP, Wilde J, Sluiter WJ, Wolffenbuttel BH, van den Ouweland JM. Thyroglobulin (Tg) recovery testing with quantitative Tg antibody measurement for determining interference in serum Tg assays in differentiated thyroid carcinoma. Clin Chem 2006;52:1196-9.
45. Verburg FA, Luster M, Cupini C, Chiovato L, Duntas LH, Elisei R, et al. Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position paper. Thyroid 2013;23:1211-25.
46. Spencer C, Petrovic I, Fatemi S. Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer. J Clin Endocrinol Metab 2011;96:1283-91.
47. Taylor KP, Parkington D, Bradbury S, Simpson HL, Jefferies SJ, Halsall DJ. Concordance between serum thyroglobulin antibody assays. Ann Clin Biochem 2011;48:367-9.
48. Giovanella L, Imperiali M, Verburg FA, Ceriani L. Evaluation of the BRAHMS Kryptor(R) thyroglobulin minirecovery test in patients with differentiated thyroid carcinoma. Clin Chem Lab Med 2013;51:449-53.
49. Preissner CM, O'Kane DJ, Singh RJ, Morris JC, Grebe SK. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assay. J Clin Endocrinol Metab 2003;88:3069-74.
50. Verburg FA, Waschle K, Reiners C, Giovanella L, Lentjes EG. Heterophile antibodies rarely influence the measurement of thyroglobulin and thyroglobulin antibodies in differentiated thyroid cancer patients. Horm Metab Res 2010;42:736-9.
51. Giovanella L, Keller F, Ceriani L, Tozzoli R. Heterophile antibodies may falsely increase or decrease thyroglobulin measurement in patients with differentiated thyroid carcinoma. Clin Chem Lab Med 2009;47:952-4.
52. Giovanella L, Suriano S, Ceriani L, Verburg FA. Undetectable thyroglobulin in patients with differentiated thyroid carcinoma and residual radioiodine uptake on a postablation whole-body scan. Clin Nucl Med 2012;36:109-12.
53. Giovanella L. False-negative thyroglobulin measurement in recurrent/metastatic thyroid carcinomas. Eur J Nucl Med Mol Imaging 2009;36:326-7.
54. Verburg FA, Lips CJ, Lentjes EG, de Klerk JM. Detection of circulating Tg-mRNA in the follow-up of papillary and follicular thyroid cancer: how useful is it? Br J Cancer 2004;91:200-4.
55. Kushnir MM, Rockwood AL, Roberts WL, Abraham D, Hoofnagle AN, Meikle AW. Measurement of thyroglobulin by liquid chromatography-tandem mass spectrometry in serum and plasma in the presence of antithyroglobulin autoantibodies. Clin Chem 2013;59:982-90.
56. Verburg FA, Stokkel MP, Duren C, Verkooijen RB, Mader U, van Isselt JW, et al. No survival difference after successful (131) I ablation between patients with initially low-risk and highrisk differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2010;37:276-83.
57. Pacini F, Molinaro E, Lippi F, Castagna MG, Agate L, Ceccarelli C, et al. Prediction of disease status by recombinant human TSH stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001;86:5686-90.
58. Souza do Rosario PW, Ribeiro Borges MA, Fagundes TA, Franco AC, Purisch S. Is stimulation of thyroglobulin (Tg) useful in low-risk patients with thyroid carcinoma and undetectable Tg on thyroxin and negative neck ultrasound? Clin Endocrinol 2005;62:121-5.
59. Persoon AC, Jager PL, Sluiter WJ, Plukker JT, Wolffenbuttel BH, Links TP. A sensitive Tg assay or rhTSH stimulated Tg: what's the best in the long-term follow-up of patients with differentiated thyroid carcinoma? PLoS One 2007;2:e816.
60. Giovanella L, Ceriani L. High-sensitivity human thyroglobulin (hTG) immunoradiometric assay in the follow-up of patients with differentiated thyroid cancer. Clin Chem Lab Med 2002;40:480-4.
61. Giovanella L, Ceriani L, Ghelfo A, Keller F, Sacchi A, Maffioli M, et al. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures. Clin Chem Lab Med 2006;44:648-52.
62. Heemstra KA, Lyu YY, Stokkel M, Kievit J, Corssmit E, Pereira AM, et al. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin Endocrinol 2007;66:58-64.
63. Chindris AM, Diehl NN, Crook JE, Fatourechi V, Smallridge RC. Undetectable sensitive serum thyroglobulin ( < 0.1 ng/ml) in 163 patients with follicular cell-derived thyroid cancer: results of rhTSH stimulation and neck ultrasonography and long-term biochemical and clinical follow-up. J Clin Endocrinol Metab 2012;97:2714-23.
64. Smallridge RC, Meek SE, Morgan MA, Gates GS, Fox TP, Grebe S, et al. Monitoring thyroglobuin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab 2007;92:82-7.
65. Spencer C, Lopresti J, Fatemi S. How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies. Curr Opinion Endocrinol Diabetes Obes 2014;21:394-404.
66. Miyauchi A, Kudo T, Miya A, Kobayashi K, Ito Y, Takamura Y, et al. Prognostic impact of serum thyroglobulin doublingtime under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid 2011;21:707-16.
67. Pacini F, Sabra MM, Tuttle RM. Clinical relevance of thyroglobulin doubling time in the management of patients with differentiated thyroid cancer. Thyroid 2011;21:691-2.
68. Wong H, Wong KP, Yau T, Tang V, Leung R, Chiu J, et al. Is there a role for unstimulated thyroglobulin velocity in predicting recurrence in papillary thyroid carcinoma patients with detectable thyroglobulin after radioiodine ablation? Ann Surg Oncol 2012;19:3479-85.
69. Giovanella L, Trimboli P, Verburg FA, Treglia G, Piccardo A, Foppiani L, et al. Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2013;40:874-80.
70. Boi F, Baghino G, Atzeni F, Lai ML, Faa G, Mariotti S. The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulating anti-Tg antibodies. J Clin Endocrinol Metab 2006;91:1364-9.
71. Sigstad E, Heilo A, Paus E, Holgersen K, Groholt KK, Jorgensen LH. The usefulness of detecting thyroglobulin in fine-needle aspirates from patients with neck lesions using a sensitive thyroglobulin assay. Diagn Cytopathol 2007;35:761-7.
72. Suh YJ, Son EJ, Moon HJ, Kim EK, Han KH, Kwak JY. Utility of thyroglobulin measurements in fine-needle aspirates of space occupying lesions in the thyroid bed after thyroid cancer operations. Thyroid 2013;23:280-8.
73. Snozek CL, Chambers EP, Reading CC, Sebo TJ, Sistrunk JW, Singh RJ, et al. Serum thyroglobulin, high-resolution ultrasound and lymph node thyroglobulin in diagnosis of differentiated thyroid carcinoma nodal metastases. J Clin Endocrinol Metab 2007;92:4278-81.